Covid-19 Research

Research Article

Serum Parameters of Primary Open Angle Glaucoma Patients in a Tertiary Hospital - A Pilot Study

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Research Article
Subject Medicine Group
OCLC JBRES Record
Ayanniyi AA*, Rauf RI, Tor AA, Jideofor CM, Abaya GJ and Alao OG
Issue: Volume7-Issue2
Pages: 1-12
Received: 2025-12-05
Accepted: 2026-02-16
Published: 2026-02-18

Abstract

Objective: To evaluate serum parameters in treatment-naive and treated Primary Open Angle Glaucoma (POAG), and no glaucoma eye patients.
Methods: Fasting blood samples of the participants were analyzed for electrolytes, proteins, urea, Blood Urea Nitrogen (BUN), creatinine, lipids, and liver enzymes.
Results: Electrolytes, including sodium, potassium, chloride, and total carbon dioxide showed no significant differences (p > 0.05). Total protein was slightly higher in treated POAG patients (7.8 ± 0.4 g/dL; p = 0.048), with elevated gamma-globulin (1.7 ± 0.2 g/dL). Urea and BUN were significantly increased in treated POAG (p = 0.011 and 0.014), while creatinine was no significantly elevated. Triglycerides were significantly higher in treated POAG (1.5 ± 0.7 mmol/L, p < 0.001); cholesterol, HDL, and LDL showed no differences. Liver enzymes were similar, though ALT was highest in treated POAG but remained within normal range.
Conclusion: These results indicate minor elevations in serum proteins, urea, BUN, and triglycerides in treated POAG patients, potentially reflecting metabolic effects of treatment. Most other parameters were comparable across groups. Findings suggest serum urea, total protein, and globulin hold promise in translational study for POAG, but larger studies are needed to confirm clinical relevance and their specificity for POAG diagnosis.

FullText HTML FullText PDF DOI: 10.37871/jbres2270 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2026 Ayanniyi AA. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Ayanniyi AA, Rauf RI, Tor AA, Jideofor CM, Abaya GJ, Alao OG.Serum Parameters of Primary Open Angle Glaucoma Patients in a Tertiary Hospital - A Pilot Study. J Biomed Res Environ Sci. 2026 Feb 18; 7(2): 12. Doi: 10.37871/jbres2270

Subject area(s)

Ophthalmology

References

  1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014 Nov;121(11):2081-90. doi: 10.1016/j.ophtha.2014.05.013. Epub 2014 Jun 26. PMID: 24974815.
  2. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014 May 14;311(18):1901-11. doi: 10.1001/jama.2014.3192. PMID: 24825645; PMCID: PMC4523637.
  3. Stein JD, Khawaja AP, Weizer JS. Glaucoma in Adults-Screening, Diagnosis, and Management: A Review. JAMA. 2021 Jan 12;325(2):164-174. doi: 10.1001/jama.2020.21899. PMID: 33433580.
  4. Michels TC, Ivan O. Glaucoma: Diagnosis and Management. Am Fam Physician. 2023 Mar;107(3):253-262. PMID: 36920817.
  5. Ayanniyi A, Mahmoud A, John-Sam O, Rauf R, Ejeba D, Akasike-Enuh R, Bisiriyu O, Afam-Osemene M, Chijioke E, Damter A, Agwadu L. The Socio-demographic and clinical profiles of patients with primary open angle glaucoma in Gwagwalada, Nigeria. Transactions of the Ophthalmological Society of Nigeria. 2024;8(1).
  6. Ayanniyi AA, Mahmoud AO, JohnSam YO, Rauf RI, Ejeba DP, Akasike-Enuh RU, Oviasu JO, Nwegbu MM. Survey of eye patients' serum for biomarkers of primary open angle glaucoma in Gwagwalada, Nigeria: serum biomarkers for primary open angle glaucoma. Int Ophthalmol. 2025 Apr 10;45(1):151. doi: 10.1007/s10792-025-03519-0. PMID: 40208393.
  7. Ayanniyi AA, Mahmoud AO, JohnSam YO, Rauf RI, Ejeba DP, Akasike-Enuh RU, Oviasu JO, Nwegbu MM. Survey of eye patients' serum for biomarkers of primary open angle glaucoma in Gwagwalada, Nigeria: serum biomarkers for primary open angle glaucoma. Int Ophthalmol. 2025 Apr 10;45(1):151. doi: 10.1007/s10792-025-03519-0. PMID: 40208393.
  8. Ayanniyi AA, Mahmoud AO, Johnsam OY, Rauf RI, Oviasu JO. Survey of eye patients' haematology parameters for possible biomarkers of primary open angle glaucoma in Gwagwalada, Nigeria. Trans Ophthalmol Soc Niger. 2023;8(1):49-57.
  9. Allison K, Patel D, Alabi O. Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future. Cureus. 2020 Nov 24;12(11):e11686. doi: 10.7759/cureus.11686. PMID: 33391921; PMCID: PMC7769798.
  10. Kapetanakis VV, Chan MP, Foster PJ, Cook DG, Owen CG, Rudnicka AR. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. Br J Ophthalmol. 2016 Jan;100(1):86-93. doi: 10.1136/bjophthalmol-2015-307223. Epub 2015 Aug 18. PMID: 26286821; PMCID: PMC4717368.
  11. Abu-Amero K, Kondkar AA, Chalam KV. An Updated Review on the Genetics of Primary Open Angle Glaucoma. Int J Mol Sci. 2015 Dec 4;16(12):28886-911. doi: 10.3390/ijms161226135. PMID: 26690118; PMCID: PMC4691082.
  12. Reina-Torres E, De Ieso ML, Pasquale LR, Madekurozwa M, van Batenburg-Sherwood J, Overby DR, Stamer WD. The vital role for nitric oxide in intraocular pressure homeostasis. Prog Retin Eye Res. 2021 Jul;83:100922. doi: 10.1016/j.preteyeres.2020.100922. Epub 2020 Nov 28. PMID: 33253900; PMCID: PMC8160027.
  13. THOMPSON GS, JONES ES. ERRORS IN THE MEASUREMENT OF SERUM ELECTROLYTES. J Clin Pathol. 1965 Jul;18(4):443-5. doi: 10.1136/jcp.18.4.443. PMID: 14318696; PMCID: PMC472975.
  14. Civan MM, Macknight AD. The ins and outs of aqueous humour secretion. Exp Eye Res. 2004 Mar;78(3):625-31. doi: 10.1016/j.exer.2003.09.021. PMID: 15106942.
  15. Seidel A, Liu L, Jiang Y, Steinle JJ. Loss of TLR4 in endothelial cells but not Müller cells protects the diabetic retina. Exp Eye Res. 2021 May;206:108557. doi: 10.1016/j.exer.2021.108557. Epub 2021 Mar 28. PMID: 33789141; PMCID: PMC8087637.
  16. Vollrath D, Liu Y. Chloride channels and glaucoma: A mini-review. Genes (Basel). 2021;12(5):714. doi: 10.3390/genes12050714.
  17. Supuran CT. Carbonic anhydrase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3467-74. doi: 10.1016/j.bmcl.2010.05.009. PMID: 20529676.
  18. Subbulakshmi S, Kavitha S, Venkatesh R. Prostaglandin analogs in ophthalmology. Indian J Ophthalmol. 2023 May;71(5):1768-1776. doi: 10.4103/IJO.IJO_2706_22. PMID: 37203029; PMCID: PMC10391402.
  19. Baudouin C, Kolko M, Melik-Parsadaniantz S, Messmer EM. Inflammation in Glaucoma: From the back to the front of the eye, and beyond. Prog Retin Eye Res. 2021 Jul;83:100916. doi: 10.1016/j.preteyeres.2020.100916. Epub 2020 Oct 17. PMID: 33075485.
  20. Tezel G, Wax MB. The immune system and glaucoma. Curr Opin Ophthalmol. 2004 Apr;15(2):80-4. doi: 10.1097/00055735-200404000-00003. PMID: 15021215.
  21. Tezel G. Immune regulation toward immunomodulation for neuroprotection in glaucoma. Curr Opin Pharmacol. 2013 Feb;13(1):23-31. doi: 10.1016/j.coph.2012.09.013. Epub 2012 Oct 19. PMID: 23084793; PMCID: PMC3529855.
  22. Weinreb RN, Liebmann JM, Martin KR, Kaufman PL, Vittitow JL. Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings. J Glaucoma. 2018 Jan;27(1):7-15. doi: 10.1097/IJG.0000000000000831. PMID: 29194198; PMCID: PMC7654727.
  23. Tektas OY, Lütjen-Drecoll E. Structural changes of the trabecular meshwork in different kinds of glaucoma. Exp Eye Res. 2009 Apr;88(4):769-75. doi: 10.1016/j.exer.2008.11.025. Epub 2008 Dec 6. PMID: 19114037.
  24. Wakefield D, Lloyd A. The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine. 1992 Jan;4(1):1-5. doi: 10.1016/1043-4666(92)90028-p. PMID: 1617154.
  25. Supuran CT, Altamimi ASA, Carta F. Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019. Expert Opin Ther Pat. 2019 Oct;29(10):781-792. doi: 10.1080/13543776.2019.1679117. Epub 2019 Oct 15. PMID: 31596641.
  26. Nislawati R, Taufik Fadillah Zainal A, Ismail A, Waspodo N, Kasim F, Gunawan AMAK. Role of hypertension as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. BMJ Open Ophthalmol. 2021 Sep 28;6(1):e000798. doi: 10.1136/bmjophth-2021-000798. PMID: 34632075; PMCID: PMC8479953.
  27. Holló G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014 Aug;15(12):1737-47. doi: 10.1517/14656566.2014.936850. Epub 2014 Jul 5. PMID: 24998246.
  28. Inoue K. Managing adverse effects of glaucoma medications. Clin Ophthalmol. 2014 May 12;8:903-13. doi: 10.2147/OPTH.S44708. PMID: 24872675; PMCID: PMC4025938.
  29. Thein AS, Hedengran A, Azuara-Blanco A, Arita R, Cvenkel B, Gazzard G, Heegaard S, de Paiva CS, Petrovski G, Prokosch-Willing V, Utheim TP, Virgili G, Kolko M. Adverse Effects and Safety in Glaucoma Patients: Agreement on Clinical Trial Outcomes for Reports on Eye Drops (ASGARD)-A Delphi Consensus Statement. Am J Ophthalmol. 2022 Sep;241:190-197. doi: 10.1016/j.ajo.2022.05.007. Epub 2022 May 18. PMID: 35594917.
  30. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010 Apr;55(4):622-7. doi: 10.1053/j.ajkd.2010.02.337. PMID: 20338463; PMCID: PMC2846308.
  31. Jeyanthi R, Rajeevan SAR, Gopal B, Tony M, Rinita. Association between primary open?angle glaucoma and serum lipid profile. Res J Med Sci. 2024;18:221?225. doi: 10.36478/makrjms.2024.7.221.225.
  32. Raza ST, Singh P, Singh L, Abbas M, Srivastava N, Mahdi F. PPAR-? and CYP46A1 genes polymorphism is associated with Primary Open Angle Glaucoma (POAG) in hypertensive North Indians. Egypt J Med Hum Genet. 2017;18(2):121-7. doi: 10.1016/j.ejmhg.2016.04.005.
  33. Cure E, Cumhur Cure M. Emerging risks of lipid-lowering therapy and low LDL levels: implications for eye, brain, and new-onset diabetes. Lipids Health Dis. 2025 May 21;24(1):185. doi: 10.1186/s12944-025-02606-6. PMID: 40399888; PMCID: PMC12093843.
  34. Oh SW, Lee S, Park C, Kim DJ. Elevated intraocular pressure is associated with insulin resistance and metabolic syndrome. Diabetes Metab Res Rev. 2005 Sep-Oct;21(5):434-40. doi: 10.1002/dmrr.529. PMID: 15651065.
  35. Li F, Luo Y, Li X, Dai Y, Xiang Q. Association between metabolic syndrome and the risk of glaucoma: a meta-analysis of observational studies. Diabetol Metab Syndr. 2024 Dec 18;16(1):300. doi: 10.1186/s13098-024-01532-4. PMID: 39696489; PMCID: PMC11657432.
  36. McCann P, Hogg RE, Fallis R, Azuara-Blanco A. The Effect of Statins on Intraocular Pressure and on the Incidence and Progression of Glaucoma: A Systematic Review and Meta-Analysis. Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2729-48. doi: 10.1167/iovs.15-18595. PMID: 27196321.
  37. Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, Devarbhavi H, Merz M, Lucena MI, Kaplowitz N, Aithal GP. Drug-induced liver injury. Nat Rev Dis Primers. 2019 Aug 22;5(1):58. doi: 10.1038/s41572-019-0105-0. PMID: 31439850.
  38. Hu CY, Lee BJ, Cheng HF, Wang CY. Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient. J Glaucoma. 2015 Apr-May;24(4):e31-3. doi: 10.1097/IJG.0000000000000185. PMID: 25333610.
  39. Schuster AK, Erb C, Hoffmann EM, Dietlein T, Pfeiffer N. The Diagnosis and Treatment of Glaucoma. Dtsch Arztebl Int. 2020 Mar 27;117(13):225-234. doi: 10.3238/arztebl.2020.0225. PMID: 32343668; PMCID: PMC7196841.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership